OncoMatch/Clinical Trials/NCT06537596
89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma
Is NCT06537596 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) for soft tissue sarcoma.
Treatment: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) — Soft Tissue Sarcoma (STS) is a cancer of soft tissues that often expresses Platelet-Derived Growth Factor Receptor (PDGFR)α, a potential therapeutic target. PDGFRα is also found in other advanced solid tumours. Olaratumab, a PDGFRα-targeted antibody, may be used to deliver radioactive isotopes for imaging or therapy. This first-in-human study will evaluate zirconium-89-labelled olaratumab (⁸⁹Zr-TLX300-CDx) for imaging in patients with STS, selected PDGFRα-positive solid tumours and identification of patients that may benefit from future treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Biomarker criteria
Required: PDGFRA expression (positive)
PDGFRα positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
anc ≥ 1500/μl, haemoglobin ≥ 9.0 g/dl, platelet count ≥ 100,000/μl
Kidney function
serum creatinine ≤ 1.5 × uln; if above uln, creatinine clearance ≥ 45 ml/min
Liver function
total bilirubin ≤ 1.5 mg/dl, ast and alt ≤ 3.0 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06537596 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require PDGFRA?
Yes, PDGFRA expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages